Funded Grants

The overall goals of the Canadian Partnership for Stroke Recovery Clinical Trials Platform is to create a national network of stroke rehabilitation clinical trial sites, help train future researchers and test potential high impact new recovery approaches.

As our brains age, they become vulnerable to diseases such as Alzheimer’s disease which can cause dementia.

Parkinson’s Disease (PD) is a debilitating neurodegenerative disease for which there is no cure.

Magnetic Seizure Therapy (MST) is a novel form of treatment that uses high intensity magnetic field pulses to stimulate the brain and induce a seizure as a therapeutic intervention for patients with depression resistant to antidepressant medication, known as Treatment Resistant Depression (TRD).

Fetal Alcohol Syndrome (FAS) is the result of in utero alcohol exposure and is characterized by central nervous system developmental impairments which causes lifelong physical and cognitive disabilities.

Autism is a neuro-developmental disorder characterized by social/communication deficits and repetitive behaviours.

Dr. Xie’s research focuses on the functional assessment of neuropsychiatric disease related synaptic genes – MDGA1 and 2. MDGAs bind to critical neuron synaptic proteins – Neuroglin (NLGN), disrupting the binding between NLGN and Neurexin (NRXN), so suppressing synaptogenesis.

Ms. Raza’s research focuses on early development in autism spectrum disorder (ASD), with the goal of identifying behavioral and physiological markers in at-risk infants.

Stroke is a life threatening emergency caused by blocked arteries that affects 45,000 Canadians a year. Each hour a stroke is left untreated means brain cells are dying.

The high and potentially increasing prevalence of Autism Spectrum Disorder (ASD) is taking a significant emotional and economic toll on patients, their families and Canadian society.